US Bancorp’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $420 | Sell |
250
-53
| -17% | -$77 | ﹤0.01% | 4062 |
|
|
2026
Q1 | $400 | Hold |
303
| – | – | ﹤0.01% | 4023 |
|
|
2025
Q4 | $567 | Hold |
303
| – | – | ﹤0.01% | 3914 |
|
|
2025
Q3 | $388 | Buy |
303
+7
| +2% | +$9 | ﹤0.01% | 3897 |
|
|
2025
Q2 | $367 | Buy |
296
+57
| +24% | +$66 | ﹤0.01% | 4027 |
|
|
2025
Q1 | $282 | Sell |
239
-525
| -69% | -$805 | ﹤0.01% | 4078 |
|
|
2024
Q4 | $1.4K | Sell |
764
-733
| -49% | -$1.43K | ﹤0.01% | 3913 |
|
|
2024
Q3 | $2.54K | Sell |
1,497
-1,510
| -50% | -$2.48K | ﹤0.01% | 3726 |
|
|
2024
Q2 | $4.12K | Buy |
3,007
+84
| +3% | +$170 | ﹤0.01% | 3574 |
|
|
2024
Q1 | $11K | Sell |
2,923
-57,777
| -95% | -$338K | ﹤0.01% | 3310 |
|
|
2023
Q4 | $595K | Buy |
60,700
+41,816
| +221% | +$342K | ﹤0.01% | 1394 |
|
|
2023
Q3 | $158K | Sell |
18,884
-1,381
| -7% | -$15.8K | ﹤0.01% | 1938 |
|
|
2023
Q2 | $270K | Buy |
20,265
+16,127
| +390% | +$196K | ﹤0.01% | 1727 |
|
|
2023
Q1 | $47.9K | Sell |
4,138
-195
| -5% | -$1.94K | ﹤0.01% | 2537 |
|
|
2022
Q4 | $35.4K | Buy |
4,333
+1,036
| +31% | +$8.93K | ﹤0.01% | 2709 |
|
|
2022
Q3 | $19K | Sell |
3,297
-231
| -7% | -$1.32K | ﹤0.01% | 3046 |
|
|
2022
Q2 | $16K | Sell |
3,528
-22,233
| -86% | -$135K | ﹤0.01% | 3184 |
|
|
2022
Q1 | $234K | Buy |
25,761
+2,469
| +11% | +$28.4K | ﹤0.01% | 1880 |
|
|
2021
Q4 | $477K | Buy |
23,292
+4,462
| +24% | +$108K | ﹤0.01% | 1547 |
|
|
2021
Q3 | $482K | Buy |
18,830
+2,778
| +17% | +$82.3K | ﹤0.01% | 1537 |
|
|
2021
Q2 | $561K | Buy |
16,052
+1,307
| +9% | +$38K | ﹤0.01% | 1490 |
|
|
2021
Q1 | $491K | Buy |
14,745
+14,308
| +3,274% | +$501K | ﹤0.01% | 1506 |
|
|
2020
Q4 | $11K | Sell |
437
-463
| -51% | -$7.87K | ﹤0.01% | 3150 |
|
|
2020
Q3 | $9K | Hold |
900
| – | – | ﹤0.01% | 3121 |
|
|
2020
Q2 | $3K | Hold |
900
| – | – | ﹤0.01% | 3443 |
|
|
2020
Q1 | $3K | Buy |
900
+500
| +125% | +$2.05K | ﹤0.01% | 3387 |
|
|
2019
Q4 | $2K | Hold |
400
| – | – | ﹤0.01% | 3492 |
|
|
2019
Q3 | $2K | Hold |
400
| – | – | ﹤0.01% | 3431 |
|
|
2019
Q2 | $2K | Hold |
400
| – | – | ﹤0.01% | 3464 |
|
|
2019
Q1 | $3K | Hold |
400
| – | – | ﹤0.01% | 3357 |
|
|
2018
Q4 | $3K | Hold |
400
| – | – | ﹤0.01% | 3328 |
|
|
2018
Q3 | $2K | Buy |
+400
| New | +$1.72K | ﹤0.01% | 3498 |
|
|
2016
Q4 | – | Sell |
-2,025
| Closed | -$18K | – | 3612 |
|
|
2016
Q3 | $18K | Hold |
2,025
| – | – | ﹤0.01% | 2855 |
|
|
2016
Q2 | $14K | Hold |
2,025
| – | – | ﹤0.01% | 2914 |
|
|
2016
Q1 | $17K | Buy |
+2,025
| New | +$19.9K | ﹤0.01% | 2824 |
|
Other funds holding PACB
AIM
NAMA
US Bancorp's PACB Position: Q2 2026 in Review
US Bancorp reduced its Pacific Biosciences (PACB) stake by 17% in Q2 2026, selling an estimated $77 and leaving 250 shares worth $420. The position accounts for ﹤0.01% of the portfolio, ranked #4062.
US Bancorp first reported a position in PACB in Q1 2016 and has held it in 35 quarters since. The position peaked at $595K in Q4 2023. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.
- US Bancorp held 250 shares of Pacific Biosciences worth $420 as of Q2 2026.
- US Bancorp sold 53 Pacific Biosciences shares in Q2 2026, an estimated $77.
- Pacific Biosciences made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #4062 holding.
- US Bancorp first reported a position in Pacific Biosciences in Q1 2016 and has held it in 35 quarters since.
- US Bancorp's Pacific Biosciences position peaked at $595K in Q4 2023.
- 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.
Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.